Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jan 15:10:906.
doi: 10.3389/fendo.2019.00906. eCollection 2019.

Hypogonadism and Cryptorchidism

Affiliations
Review

Hypogonadism and Cryptorchidism

Wiwat Rodprasert et al. Front Endocrinol (Lausanne). .

Abstract

Congenital cryptorchidism (undescended testis) is one of the most common congenital urogenital malformations in boys. Prevalence of cryptorchidism at birth among boys born with normal birth weight ranges from 1.8 to 8.4%. Cryptorchidism is associated with a risk of low semen quality and an increased risk of testicular germ cell tumors. Testicular hormones, androgens and insulin-like peptide 3 (INSL3), have an essential role in the process of testicular descent from intra-abdominal position into the scrotum in fetal life. This explains the increased prevalence of cryptorchidism among boys with diseases or syndromes associated with congenitally decreased secretion or action of androgens, such as patients with congenital hypogonadism and partial androgen insensitivity syndrome. There is evidence to support that cryptorchidism is associated with decreased testicular hormone production later in life. It has been shown that cryptorchidism impairs long-term Sertoli cell function, but may also affect Leydig cells. Germ cell loss taking place in the cryptorchid testis is proportional to the duration of the condition, and therefore early orchiopexy to bring the testis into the scrotum is the standard treatment. However, the evidence for benefits of early orchiopexy for testicular endocrine function is controversial. The hormonal treatments using human chorionic gonadotropin (hCG) or gonadotropin-releasing hormone (GnRH) to induce testicular descent have low success rates, and therefore they are not recommended by the current guidelines for management of cryptorchidism. However, more research is needed to assess the effects of hormonal treatments during infancy on future male reproductive health.

Keywords: Leydig cell; Sertoli cell; gonadotropins; testosterone; undescended testis.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Testicular locations. Normally, both testes locate at the bottom of the scrotum. In cryptorchidism, one or both testes do not stay at the normal position, but anywhere along the normal path of testicular descent as illustrated in the figure.

References

    1. Foresta C, Zuccarello D, Garolla A, Ferlin A. Role of hormones, genes, and environment in human cryptorchidism. Endocr Rev. (2008) 29:560–80. 10.1210/er.2007-0042 - DOI - PubMed
    1. Virtanen HE, Toppari J. Epidemiology and pathogenesis of cryptorchidism. Hum Reprod Update. (2008) 14:49–58. 10.1093/humupd/dmm027 - DOI - PubMed
    1. Sijstermans K, Hack WW, Meijer RW, van der Voort-Doedens LM. The frequency of undescended testis from birth to adulthood: a review. Int J Androl. (2008) 31:1–11. 10.1111/j.1365-2605.2007.00770.x - DOI - PubMed
    1. Lee PA, Coughlin MT. Fertility after bilateral cryptorchidism. Evaluation by paternity, hormone, and semen data. Horm Res. (2001) 55:28–32. 10.1159/000049960 - DOI - PubMed
    1. Trabert B, Zugna D, Richiardi L, McGlynn KA, Akre O. Congenital malformations and testicular germ cell tumors. Int J cancer. (2013) 133:1900–4. 10.1002/ijc.28207 - DOI - PMC - PubMed

LinkOut - more resources